Services within cardiovascular diseases

Investigate the efficacy of your potential novel agents in
rodent models of cardiovascular disease (CVD).

AngII/PE model

  • Lean male C57BL/6J mice on normal chow diet.
  • Co-Infusion with angiotensin II and α-adrenergic agonist phenylephrine for a total of 28 days.
  • Cardiac hypertrophy with systolic and diastolic dysfunction including reduced ejection fraction.
  • Extensive perivascular/interstitial myocardial fibrosis.
  • Therapeutic evaluation of drug efficacy.

Atherosclerosis model

  • Genetically modified mouse models (ApoE-/- or LDL r-/-) on western diet
  • Hypercholesterolemia
  • Obesity and glucose intolerance
  • Plaque volume quantification and composition incl. 3D spatial mapping
  • “En face” plaque area quantification of the aortic arch using Oil-Red-O staining​

Get in touch

Please get in touch if you are interested in discussing how to get started with your study. Reach out to Director Michael Feigh Ph. +45 2382 9493

Fully equipped platform for cardiovascular characterization

We have a unique combination of state-of-the art in vivo, ex vivo and in vitro methodologies that can be individually combined to evaluate drug efficacy in cardiovascular diseases.

The study design can be modified to meet your exact needs.


Related Links:

Main offerings


  • State-of-the art echocardiography using a high-resolution imaging platform incl. assessment of cardiac function in 2D, 4D and strain imaging.
  • 3D imaging of aortic plaque lesion and inflammation.
  • Histological evaluation of fibrotic and arteriosclerotic changes in the myocardium.
  • 3D imaging of the intact mouse heart incl. quantification of cardiac wall and cavity volumes, infarct volume and capillary density.
  • Single-cell and bulk myocardial RNA sequencing.
  • Measurement of clinically-relevant plasma markers of cardiomyocyte damage and stretch.

Get in touch

Please get in touch if you are interested in discussing how to get your study started.

Michael Feigh

+45 2382 9493